Avai Bio (AVAI) Common Equity (2018 - 2026)

Avai Bio has disclosed Common Equity across 9 years of filings, most recently posting -$3.2 million for Q2 2026.

• In Q2 2026, Common Equity fell 61.82% year-over-year to -$3.2 million; the TTM figure through Jun 2026 stood at -$3.2 million (down 61.82% YoY), while the FY2026 annual figure was -$2.8 million, down 80.01% from the prior year.
• Common Equity came in at -$3.2 million for Q2 2026 at Avai Bio, down from -$2.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $2.1 million in Q4 2024 to a low of -$3.2 million in Q2 2026.
• Average Common Equity over 5 years is -$1.1 million, with a median of -$1.2 million recorded in 2023.
• Year-over-year, Common Equity tumbled 754.19% in 2022 and soared 283.14% in 2024.
• Over 5 years, Common Equity stood at -$539482.0 in 2022, then tumbled by 159.67% to -$1.4 million in 2023, then jumped by 252.45% to $2.1 million in 2024, then sank by 230.85% to -$2.8 million in 2025, then declined by 15.32% to -$3.2 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were -$3.2 million in Q2 2026, -$2.8 million in Q1 2026, and -$2.8 million in Q4 2025.